Bisphosphonate antifracture efficacy

[1]  F. Bauss,et al.  Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis , 2006, Therapeutics and clinical risk management.

[2]  S. K. Brenneman,et al.  The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA) , 2006, Osteoporosis International.

[3]  M. Drezner,et al.  Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study , 2005, Annals of the rheumatic diseases.

[4]  D. Felsenberg,et al.  Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. , 2005, Bone.

[5]  J. Reginster,et al.  Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  Dieter Felsenberg,et al.  Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  Jacques P. Brown,et al.  Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis , 2004, Current medical research and opinion.

[9]  O. Johnell,et al.  Excess mortality after hospitalisation for vertebral fracture , 2004, Osteoporosis International.

[10]  R. Recker,et al.  Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study , 2004, Osteoporosis International.

[11]  J. Kanis,et al.  Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  R. Temple,et al.  Study Designs in Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  Nancy J. Dickey,et al.  Is the Use of Placebo Controls Ethically Permissible in Clinical Trials of Agents Intended to Reduce Fractures in Osteoporosis? , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  J. Cannata-Andía,et al.  The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population , 2003, Osteoporosis International.

[15]  F Melsen,et al.  Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. , 2002, Bone.

[16]  R. Rizzoli.  Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  Jacques P. Brown,et al.  The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis , 2002, Calcified Tissue International.

[18]  C. Cooper,et al.  Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study , 2002, Osteoporosis International.

[19]  M. Hochberg,et al.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[21]  L. Melton,et al.  Who Has Osteoporosis? A Conflict Between Clinical and Public Health Perspectives , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[23]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis , 2000, Aging.

[24]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .

[25]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[26]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[27]  O. Johnell,et al.  Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) , 1999, Osteoporosis International.

[28]  M. Rogers,et al.  Bisphosphonates: from the laboratory to the clinic and back again. , 1999, Bone.

[29]  H K Genant,et al.  Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. , 1999, Archives of internal medicine.

[30]  J Pearson,et al.  Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[32]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[33]  Lynn Wei,et al.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.

[34]  O Johnell,et al.  The socioeconomic burden of fractures: today and in the 21st century. , 1997, The American journal of medicine.

[35]  P. Ross,et al.  Clinical consequences of vertebral fractures. , 1997, The American journal of medicine.

[36]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[37]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[38]  O. Johnell,et al.  Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men , 2005, Osteoporosis International.

[39]  O. Johnell,et al.  Mortality after osteoporotic fractures , 2004, Osteoporosis International.

[40]  O. Johnell,et al.  Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture , 2001, Osteoporosis International.

[41]  P. Miller,et al.  Antifracture efficacy of antiresorptive agents are related to changes in bone density. , 2000, The Journal of clinical endocrinology and metabolism.

[42]  R. Rizzoli,et al.  Weekly administration of alendronate: rationale and plan for clinical assessment. , 2000, Clinical therapeutics.

[43]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[44]  A. Silman,et al.  Mortality Associated with Vertebral Deformity in Men and Women: Results from the European Prospective Osteoporosis Study (EPOS) , 1998, Osteoporosis International.